• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients
 
  • Details
  • Full
Options
November 25, 2024
Journal Article
Title

Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients

Abstract
Background: The clinical management of breast cancer (BC) is mainly based on the assessment of receptor expression by tumour cells. However, there is still an unmet need for novel biomarkers important for prognosis and therapy. The tumour immune microenvironment (TIME) is thought to play a key role in prognosis and therapy selection, therefore this study aimed to describe the TIME in Ethiopian BC patients.
Methods: RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue from 82 women with BC. Expression of PAM50 and 54 immune genes was analysed using the Nanostring platform and differentially expressed genes (DEGs) were determined using ROSALIND®. The abundance of different cell populations was estimated using Nanostring's cell type profiling module, while tumour infiltrating lymphocytes (TILs) were analysed using haematoxylin and eosin (H&E) staining. In addition, the PIK3CA gene was genotyped for three hotspot mutations using qPCR. Kaplan-Meier survival analysis and log-rank test were performed to compare the prognostic relevance of immune subgroups.
Results: Four discrete immune phenotypes (IP1-4) were identified through hierarchical clustering of immune gene expression data. These IPs were characterized by DEGs associated with both immune activation and inhibition as well as variations in the extent of immune infiltration. However, there were no significant differences regarding PIK3CA mutations between the IPs. A downregulation of immune suppressive and activating genes and the lowest number of infiltrating immune cells were found in IP2, which was associated with luminal tumours. In contrast, IP4 displayed an active TME chracterized by an upregulation of cytotoxic genes and the highest density of immune cell infiltrations, independent of the specific intrinsic subtype. IP1 and IP3 exhibited intermediate characteristics. The IPs had a prognostic relevance and patients with an active TME had improved overall survival compared to IPs with a significant downregulation of the majority of immune genes.
Conclusion: Immune gene expression profiling identified four distinct immune contextures of the TME with unique gene expression patterns and immune infiltration. The classification into distinct immune subgroups may provide important information regarding prognosis and the selection of patients undergoing conventional treatments or immunotherapies.
Author(s)
Yohannes, Meron
Addis Ababa University
Desalegn, Zelalem
Addis Ababa University
Bauer, Marcus
Martin-Luther-Universität Halle-Wittenberg  
Stückrath, Kathrin
Martin-Luther-Universität Halle-Wittenberg  
Anberbir, Endale
Addis Ababa University
Bekuretsion, Yonas
Addis Ababa University
Assefa, Mathewos
Addis Ababa University
Wakuma, Tariku
Aira Hospital
Worku, Yasin
Wollo University
Santos, Pablo S.C.
Martin-Luther-Universität Halle-Wittenberg  
Taylor, Lesley
City Of Hope National Medical Center
Adissie, Adamu
Martin-Luther-Universität Halle-Wittenberg  
Wickenhauser, Claudia
Martin-Luther-Universität Halle-Wittenberg  
Massa, Chiara  
Martin-Luther-Universität Halle-Wittenberg  
Vetter, Martina  
Martin-Luther-Universität Halle-Wittenberg  
Kantelhardt Eva Johanna  
Martin-Luther-Universität Halle-Wittenberg  
Seliger, Barbara  
Martin-Luther-Universität Halle-Wittenberg  
Abebe, Tamrat
Addis Ababa University
Journal
Breast cancer research. Online journal  
Open Access
DOI
10.1186/s13058-024-01916-4
Additional link
Full text
Language
English
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Keyword(s)
  • Breast cancer

  • Ethiopia

  • Immune phenotypes

  • PAM50

  • Tumor immune microenvironment

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024